Tyrosine kinase inhibitorFDA-approvedFirst-line
Brafi
Generic name: vemurafenib
How it works
Blocks the activity of the BRAF V600E mutation in melanoma cells, preventing cancer growth.
Cancer types
Melanoma— BRAF V600E mutation-positive
Efficacy
In clinical trials, around 50% of patients with BRAF V600E mutation achieved an objective response, with median progression-free survival of approximately 6 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Hairy Cell Leukemia | Leukemia | phase-2 | — | Source → |
| Melanoma Cells Resist Vemurafenib through Mitochondrial Changes | Melanoma | lab-study | — | Source → |
| New Compound May Help Fight Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Vemurafenib May Help Fight Melanoma by Triggering Cell Death | Melanoma | lab-study | — | Source → |
| Researchers Identify New Way to Overcome Resistance to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Researchers Create Melanoma Cell Lines Resistant to Cancer Treatment | Melanoma | lab-study | — | Source → |
| Real-world study of melanoma treatment in Germany | Melanoma | observational | Median overall survival was 21.6 months in patients without brain metastases and 7.4 months in patients with brain metastases. | Source → |
| Cobimetinib Plus Vemurafenib Shows Antitumor Activity in Advanced Solid Tumors | Melanoma | phase-2 | The disease control rate was 68% and the objective response rate was 57%. | Source → |
| USP18 may help melanoma cells resist cancer treatment | Melanoma | lab-study | — | Source → |
| New Vemurafenib Derivatives Show Promise as Melanoma Treatment | Melanoma | lab-study | — | Source → |
| Switching to Atezolizumab After 3 Months May Not Help Advanced Melanoma Patients | Melanoma | phase-2 | Median progression-free survival was 13.9 months in patients who continued vemurafenib plus cobimetinib, compared to 5.9 months in those who switched to atezolizumab. | Source → |
| Researchers Identify Potential Target for Overcoming Melanoma Resistance | Melanoma | lab-study | — | Source → |
| Combination Therapy Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The disease control rate was 52% (95% CI, 35 to 65), and the objective response rate was 30% (95% CI, 14 to 50). | Source → |
| New way to deliver cancer drugs to melanoma cells | Melanoma | lab-study | Both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines. | Source → |
| Alternative mRNA Splicing in Melanoma Cells Resistant to Vemurafenib | Melanoma | lab-study | — | Source → |
| Vemurafenib's Side Effect Linked to Enzyme Inhibition | Melanoma | lab-study | — | Source → |
| BRAF Inhibitor Resistance Linked to Protein PYK2 in Melanoma | Melanoma | lab-study | Increased expressions of p-PYK2 in melanoma patients were positively correlated with advanced stage (p = 0.002), metastasis (p < 0.001), and Clark grade (p < 0.001), and were also associated with short overall survival [hazard ratio (HR) = 3.304, p = 0.007] and progression-free survival (HR = 2.930, p = 0.001). | Source → |
| Combining Palbociclib and Vemurafenib in Metastatic Melanoma Treatment | Melanoma | phase-1/2 | The median progression-free survival was 2.8 months, and 5 (27.8%) patients showed a clinical response. | Source → |
| Vemurafenib May Help Hairy Cell Leukemia Patients Before Standard Treatment | Leukemia | observational | After a standard course of cladribine chemotherapy, 18 patients (90%) experienced complete clinical remission and 2 patients (10%) experienced partial remission with residual splenomegaly. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.